News

Conducted by the ECOG-ACRIN Cancer Research Group as part of Exelixis’ collaboration with the US National Cancer Institute (NCI), the Study E1512 is a randomized phase II trial

In CheckMate -017, at one year, Opdivo showed an overall survival rate of 42% versus 24% for docetaxel, with a median overall survival of 9.2 months versus six

The product will be launched under the name Junel Fe 24 (norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets) and is currently available in the

MM-398 is a new, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. The filing follows the recent submissions of NDA and marketing authorization application (MAA) by its

The trial is designed to evaluate the benefit of Kyprolis administered once-weekly with dexamethasone versus the current FDA-approved twice-weekly administration schedule in patients who have received prior treatment

PARP, or poly (ADP-ribose) polymerase, is a DNA repair protein that restores single strand DNA breaks and by inhibiting PARP, certain cancer cells may be rendered unable to

The trial will evaluate the safety and preliminary efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Lilly’s vascular endothelial growth factor (VEGF) Receptor 2

Argatroban Injection is an anticoagulant indicated for prophylaxis or treatment of thrombosis in adult patients with heparin induced thrombocytopenia (HIT), or as an anticoagulant in adult patients with

Results from the Phase 3 PALOMA-3 study will be featured today in a press briefing during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)